Forbion’s Post

Flagship Pioneering, one of the largest firms investing in and creating new biotech companies, said Wednesday that it has raised $3.6 billion in new funding. Flagship’s fundraising is a high point in the broader biotech VC ecosystem, which has faced headwinds, thanks to the biotech market downturn and larger economic shifts in the U.S. What do you think about the future of life science VC fundraising? Will other firms be able to raise mega-funds like Flagship? #biotech #biopharma #lifesciences #fundraising #VC #privateequity #venturestrategies #venturefundraising

DON Healthcare launches new VC and Family Office Network that has already exceeded 500 companies and growing. DON Healthcare has collated and evaluated over 500 of the most important Venture Capital Firms and Family Offices at the decision-maker level seeking to invest in healthcare opportunities. This live and interactive Network, staffed by actual account managers, links entrepreneurs and CEOs with appropriate venture capital firms. More information - https://lnkd.in/e6yBYmii #ceos #healthcare #biotech #medtech #fundraising

🔥 Join us for the 3rd H7 Angel Club meeting in 2024, happening on July 2nd at 3pm PST via Zoom！  🚩 Featured Company: A next-generation Non-degrading #MolecularGlue platform with significant competitive advantages. Founded by a pioneer who co-established the molecular glue field 33 years ago, the company recently secured a $28M #oversubscribed Series A+ round led by 3E Bioventures, Proxima Ventures, and Lapam Capital. 📣 H7 investment team has thoroughly reviewed the project and prepared a 📝[One-Pager Investment Teaser] along with a comprehensive ✍️ [Investment Report exceeding 30 pages]. Upon signing and NDA, we are delighted to provide access to the full report.  ----------- The meeting is exclusively for investor members of H7 Angel Club, which is entirely free for qualified investors. Apply for membership to attend. Upon approval, you’ll receive further details. 🎯Investor Membership Application: https://shorturl.at/losSW 🎯Founders Submitting Their Deck: https://shorturl.at/d3UBO #angel #investmentopportunity #vc #healthcare #lifesciences #medtech #medicaldevices #biotech #biopharma #investors #familyoffice #syndicate #fundraising #clinical

🔥 Join us for the 3rd H7 Angel Club meeting in 2024, happening on July 2nd at 3pm PST via Zoom！  🚩 Featured Company: A next-generation Non-degrading #MolecularGlue platform with significant competitive advantages. Founded by a pioneer who co-established the molecular glue field 33 years ago, the company recently secured a $28M #oversubscribed Series A+ round led by 3E Bioventures, Proxima Ventures, and Lapam Capital. 📣 H7 investment team has thoroughly reviewed the project and prepared a 📝[One-Pager Investment Teaser] along with a comprehensive ✍️ [Investment Report exceeding 30 pages]. Upon signing and NDA, we are delighted to provide access to the full report.  ----------- The meeting is exclusively for investor members of H7 Angel Club, which is entirely free for qualified investors. Apply for membership to attend. Upon approval, you’ll receive further details. 🎯Investor Membership Application: https://shorturl.at/losSW 🎯Founders Submitting Their Deck: https://shorturl.at/d3UBO #angel #investmentopportunity #vc #healthcare #lifesciences #medtech #medicaldevices #biotech #biopharma #investors #familyoffice #syndicate #fundraising #clinical

Atlas Venture, which counts 56 portfolio biotechs, is looking at keeping its 14th fund the same size as its 13th: $450 million. The firm had progressively increased the size of its last few funds but is looking at a "disciplined" new fund, according to an annual review presentation posted on Monday, Nov. 18. Atlas raised $280 million for its 10th fund in 2015, $350 million in 2017, $400 million in 2020 and then $450 million for its 13th batch in 2022. Atlas has been quite active in 2024. It has disclosed investments in about a dozen private biotechs, according to the presentation. One of those, obesity biotech Kailera, secured one of the industry’s largest private funding rounds of this year. About 10 more have been made in stealth mode, according to the presentation. #biotech #biotechventurecapital #lifesciencesvc #biotechvc #atlasventure

🏆 Attention all European Life Science Innovators 🏆 Nominations are open for the Late Stage Venture Round / Series C (and beyond) Finance Raise of the Year award at the European Lifestars Awards! This is your chance to highlight a company that has made significant strides in late-stage private fundraising, shaping the future of life sciences with their groundbreaking achievements! This prestigious award recognizes companies that have excelled in the following areas: 💰 Amount of funds raised 🏃♂️ Process / speed / allocation fulfillment of securing significant new funds 🤝 Level / reputation of investors attracted 💼 Post-finance allocation / use of proceeds 🌟 Level of value creation / value realization from the raise To qualify you must - Be a fundraise by a private company - Have raised the funds in the period between 1 September 2023 and 1 August 2024 - Be a company with European headquarters Nominate a deserving company today and help us celebrate their dedication to innovation and growth in the European life sciences landscape! Cast your nomination here: https://lnkd.in/ezjTkn6f Watch the video of last year’s winner, Apollo Therapeutics, and get inspired by their success. Then, cast your nominations for this year’s standout performer! #LifestarsAwards #Innovation #LifeSciences #SeriesC #Fundraising 

📰 Saturday Read: Biopharma’s $17B VC surge – and Earlybird Health is part of it! In 2024, healthcare VC has reached new heights, with over $17 billion raised by at least 25 firms to fuel innovations in the biopharma industry. 🧬 As Stephen Hansen highlighted in a recent BioCentury Inc. article, this capital is powering diverse therapy areas, from digital health and therapeutics to diagnostics and rare diseases. A key trend? 9 of these funds specifically target AI/ML or digital health. We’re proud to see our Earlybird Health Team recognized for their latest fund announced in February, alongside VCs like Forbion, Kurma Partners, Asabys Partners, Seroba., and more. 👀 For more insights, check out the full report (available for subscribers) at https://bit.ly/3BW6E6f Cc: Thom Rasche, John Yianni, Florent Gros, Dr. Christoph Massner, Rabab Nasrallah, PhD, Elisheva Marcus, Elena Marchesi #Biopharma #Startups #VC

FUNDING NEWS: "Three Utah Firms — Paiv, Paramify, and Paterna Biosciences — Have Raised a Combined $14.5 Million in Seed Round Funding." On a per company basis, 🔹 Paiv (formerly #Gamify) raised $5.0 million, 🔹 Paramify raised $3.5 million, and 🔹 Paterna Biosciences raised $6.0 million. To get a rundown on what each firm is focused on, as well as the firms that invested in each of the respective companies, we invite you to visit Utah Money Watch to read https://lnkd.in/gyuSN4hE. As always, if you find our writeup useful and/or informative, we hope you'll take a moment or two to #repost it, #share it, #comment, and/or #like it. {Doing so is helpful with boosting the social media algorithms, btw.} Last of all, if you have not yet #subscribed to Utah Money Watch, we encourage you to do so today. Simply click here - www.utahmoneywatch.com - then click on a #Subscribe button on any page on the website, then fill in 2 fields. At most, it should take 30 seconds to sign-up. Anyway ... thanks for your continued interest and support. Sincerely, David ("Poppa P") Politis, Publisher, Editor, & Founder, Utah Money Watch #utah #funding #vc #venturecapital #money #monetary #financing #saas #salestech #compliance #regulatory #biotech #healthcare #IVF #invitrofertilization

While the investment climate in the life science industry has shown signs of improvement in 2024, biotechs continue to face tough competition for investment. With VCs receiving an overwhelming number of opportunities, they have more options than ever before. That’s why it’s crucial to have the right strategy, positioning, and narrative when approaching investors. At Liberi Group, we have the expertise to help you address these challenges and assist with the fundraising efforts. Let’s connect and explore the collaboration opportunities together. #businessdevelopment #biotech #fundraising #pharma #LiberiGroup #VC

🤑 🤑 🤑 $17B+ raised in new VC biopharma funds so far in 2024, according to the latest Stephen Hansen analysis in BioCentury Inc. 🤑 🤑 🤑 Since the article’s publication this afternoon, I’ve already received 4 calls — 2 from VCs and 2 from private biopharmas — requesting access to underlying data and insights into how these funds are being deployed. BONUS: Our BioCentury BCIQ database provides the underlying data enabling you to run your own queries with your set of assumptions. Key takeaways from the article: 💹 $3.6B raised by Flagship Pioneering: The largest fund close of 2024, including $2.6B for Fund VIII and $1B for side funds. 💹 $3B raised by Arch Venture Partners: Another major player, focusing on early-stage innovation. 💹 €2.1B raised by Forbion: Includes €1.2B for Forbion Growth Opportunities Fund III, the largest European biopharma fund ever. 💹 Focus on AI/ML and digital health: Nine of the funds are geared toward advancing AI and digital health technologies. 💹 Late-stage & growth equity: Fourteen of the funds have a mandate for late-stage or growth equity investments, highlighting a broader shift in capital deployment. #VentureCapital #Biopharma #Investment #Biotech #AI Link to article and analysis in COMMENTS 👇👇👇